Table 1. Efficacy of ICIs and diagnostic methods in patients with ALK/RET/ROS1-rearranged positive NSCLC.
| Reference | Gene rearrangement | Treatment | ORR | Median PFS (months) | Diagnostic methods used for molecular testing | Details of ICI-benefiting cases |
|---|---|---|---|---|---|---|
| Multicenter analysis by Mazieres et al. (2) | ALK (n=23), RET (n=16), ROS1 (n=7) | ICI monotherapy | 0% (ALK), 6% (RET), 17% (ROS1) | 2.5 (ALK), 2.1 (RET), NA (ROS1) | Local testing on validated platforms | NAa |
| Multicenter analysis by Negrao et al. (4) | ALK (n=19), RET (n=14), ROS1 (n=3) | ICI monotherapy | NA | 2.7 (overall) | CLIA certified laboratory assays (most of them were FoundationOne assays) | NA |
| Single-center analysis by Dudnik et al. (7) | RET (n=4), ROS1 (n=1) | ICI monotherapy | 0% (RET), NA (ROS1) | 3 (RET), 0.1 (ROS1) | FoundationOne assay | NA |
| Flatiron health electronic health record analysis by Jahanzeb et al. (11) | ALK (n=83) | ICI monotherapy (n=74) or ICI chemo (n=9) | NA | 2.3 | Not specified | NA |
| Flatiron health electronic health record analysis by Bodor et al. (12) | ALK (n=65) | ICI monotherapy (n=65) | NA | 2.3 | Not specified | NA |
| Single-center analysis by Oya et al. (13) | ALK (n=7) | ICI monotherapy | NA | 1.8 | RT-PCR, IHC, or FISH | NA |
| Single-center analysis by Gainor et al. (14) | ALK (n=6) | ICI monotherapy | 0% | NA | FISH | Not applicable |
| Multicenter analysis by Guisier et al. (6) | RET (n=9) | ICI monotherapy | 38% | 7.6 | FISH | NA |
| Single-center analysis by Offin et al. (15) | RET (n=16) | ICI monotherapy (n=15), dual ICIs (n=1) | 0% | 3.4 | MSK-IMPACT, FoundationOne, multiplex PCR, FISH, or RT-PCR | NA |
| Single-center analysis by Lee et al. (16) | RET (n=13) | ICI monotherapy (n=12), dual ICIs (n=1) | 7.7% | 2.1 | FISH or NGS | Available |
| Single-center analysis by Uehara et al. (5) | RET (n=2) | ICI chemo (n=2) | 50% | NA | NGS (Oncomine Dx Target Test) | NA |
| Multicenter analysis by Choudhury et al. (17) | ROS1 (n=39) | ICI monotherapy (n=28), ICI chemo (n=11) | 13% (ICI monotherapy), 83% (ICI chemo) | 2.1 (ICI monotherapy), 10 (ICI chemo) | FISH or NGS. The details of NGS panels were described in the paper | Available |
a, it is available in the article that accompanies this editorial (9). ICI, immune checkpoint inhibitors; NSCLC, non-small cell lung cancer; ORR, overall response rate; PFS, progression-free survival; NA, not available; CLIA, clinical laboratory improvement amendment; chemo, chemotherapy; RT-PCR, reverse transcription polymerase chain reaction; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; NGS, next-generation sequencing.